Skip to main content
Pratiti Bandopadhayay, MD, Pediatric Hematology & Oncology, Boston, MA

Pratiti Bandopadhayay MD


Instructor, Pediatrics-Children's Hospital, Harvard Medical School

Join to view full profile
  • 450 Brookline AveDana Farber Cancer Centre-Pediatric Neuro-OncBoston, MA 02215

  • Phone+1 857-600-5911

Join Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 11 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Pratiti Bandopadhayay, MD is a pediatric hematologist/oncologist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts. She is affiliated with Dana-Farber Cancer Institute and Boston Children's Hospital.

Education & Training

  • Monash University Faculty of Medicine
    Monash University Faculty of MedicineClass of 2001

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2013 - 2028

Publications & Presentations

PubMed

Press Mentions

  • Dana-Farber Research Shows Promise for Targeted Therapies for Paediatric Gliomas
    Dana-Farber Research Shows Promise for Targeted Therapies for Paediatric GliomasAugust 4th, 2025
  • Dana-Farber Research Shows Promise for Targeted Therapies for Pediatric Gliomas
    Dana-Farber Research Shows Promise for Targeted Therapies for Pediatric GliomasJuly 31st, 2025
  • $75,000 Hannah’s Heroes Grant Given to Cancer Researcher
    $75,000 Hannah’s Heroes Grant Given to Cancer ResearcherOctober 16th, 2017

Grant Support

  • Protein O' Mannosylation as a therapeutic vulnerability in KIAA1549-BRAF-driven pediatric low-grade gliomaDANA-FARBER CANCER INST2026–2031
  • Targeting vulnerabilities of PPM1D-mutant gliomasDANA-FARBER CANCER INST2026–2028
  • Targeting vulnerabilities of PPM1D-mutant gliomasDANA-FARBER CANCER INST2026–2028